Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms COLUMBA
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 04 Dec 2018 Results assessing activation of adaptive and innate immunity in daratumumab and IMiDs treated MM patients from MMY3012 and MM014 trial, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 25 Apr 2018 According to a Genmab media release, data from the study will be presented at the 2018 ASCO Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top